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Summary
 
Tumor necrosis factor (TNF) and lymphotoxin (LT) are highly pleiotropic cytokines that play
a central role in regulating HIV-1 replication. These cytokines express their activities through
two membrane receptors, TNFR60 (p55-60) and TNFR80 (p75-80). In the present study we
have demonstrated by means of antagonistic and agonistic receptor-specific antibodies that in
latently infected lymphocytic (ACH-2) cells the TNFR60 plays a dominant role in signaling
HIV production, although selective activation of TNFR80 by receptor-specific antibodies can
also induce HIV production. Unexpectedly, when both TNFRs were activated simultaneously
by agonistic antibodies or coculture with cells expressing a noncleavable membrane form of
TNF, HIV production was downregulated and induction of cell death was enhanced in ACH-2
cells. More relevant, in vitro HIV-infected peripheral blood lymphocytes cocultured with cells
expressing membrane TNF underwent rapid induction of apoptosis with a subsequent reduced
HIV production of these lymphocytes cultures. This was not observed with HIV-infected lym-
phocytes treated with soluble TNF. These data provide evidence for the differential trigger po-
tential of membrane versus soluble TNF and show that TNFR80 is an important modulator of
TNF responsiveness of HIV-infected T cells via cooperative signaling with TNFR60.
 
T
 
NF is suspected to play an important role in HIV in-
fection and progression of AIDS. This reasoning is
based on the finding that TNF enhances or induces HIV
replication in vitro in chronically infected, established cell
lines and in freshly isolated peripheral blood mononuclear
cells from HIV-infected individuals (1–4). On the other
hand, it has been reported that, in vitro, HIV infection
stimulates TNF gene expression and protein production
(5). This finding is in accordance with a clinical correlation
of enhanced TNF serum levels and disease state (6). It is
conceivable that an autocrine-positive feedback loop exists
between HIV infection and TNF production, in which
TNF would act as a progression factor of virus replication.
Aside from this direct influence of TNF on the HIV repli-
cation cycle, it is apparent that several of the AIDS associ-
ated pathophysiological changes observed during late stages
of the disease (e.g., cachexia and neurodegeneration) are
correlated with and could be due to chronically elevated
TNF levels (reviewed in reference 7).
Lymphotoxin (LT)
 
1
 
, which is structurally and function-
ally similar to TNF, has also been shown to activate HIV
replication in vitro (3, 8). Both cytokines, TNF and LT,
share the same membrane receptors for initiation of their
cellular responses, the 55–60-kD TNF receptor 1 (TNFR60)
and the 75–80 kD TNF receptor 2 (TNFR80) (9, 10).
Both TNFRs are coexpressed in many tissues including he-
matopoietic cells, although membrane expression is inde-
pendently regulated and may differ considerably, depend-
ing on the cell type (11–13). The individual contribution
of the two TNFRs to TNF responses is not yet fully un-
derstood. In vitro models indicate that both receptors acti-
vate distinct signal pathways and can be functional on their
own (14–16), but may also cooperate at the level of recep-
tor-ligand interaction (17) and at the level of signal trans-
duction (16).
With respect to TNF-mediated enhancement of virus
production or induction of latent HIV, the critical role of
NF-
 
k
 
B in this process has been shown for T lymphocytes and
monocytes/macrophages as well as for neuronal cells (18–22).
As TNF activation of NF-
 
k
 
B appears predominantly medi-
ated via TNFR60-linked pathways (23–25), a role of this
TNFR subtype in TNF-mediated HIV replication can be
assumed and has been shown for a monocytic cell line (26),
whereas the role of TNFR80 remained unclear. This is of
particular interest, as TNFR80 is the prevailing TNFR sub-
 
1
 
Abbreviations used in this paper:
 
 FDA, fluorescein diacetate; LT, lympho-
toxin; RT, reverse transcriptase.
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type in normal T cells, whereas cells of the myelomonocytic
lineage usually express equal levels of both TNFRs (12, 27).
To understand whether both TNFRs are capable to
transmit signals relevant to modulation of HIV replication,
we have employed the natural ligand TNF in a soluble and
in a stably membrane integrated form as well as LT
 
a
 
. Fur-
ther, agonistic and antagonistic, receptor subtype-specific
antibodies were used to mimic and block, respectively,
TNF/LT
 
a
 
 action. For these studies the T cell line ACH-2
was used as a model of postintegration HIV latency (re-
viewed in 28). This cell line has a very low basal level of
HIV production, which is enhanced dramatically by exter-
nal stimuli, in particular TNF or inducers of endogenous
TNF (29), and has previously been used to study inhibition
of TNF-mediated HIV replication by soluble TNFR con-
structs (30). In a second model, we have used in vitro acti-
vated and HIV-infected peripheral blood T cells to study
the response to the 26-kD membrane expressed form of TNF,
which has been recently shown to differ from soluble TNF
in its receptor binding and cellular activation capacity (31).
 
Materials and Methods
 
Cell Lines.
 
The ACH-2 cell line (HIV-1 latent T-cell clone; 32)
and the parental cell line CEM-SS were obtained from Dr. Thomas
M. Folks, through the AIDS Research and Reference Reagent
Program (Rockville, MD). The cells were propagated in RPMI-
1640 (Gibco, Paisley, Scotland), 50 U/ml penicillin, 50 
 
m
 
g/ml strep-
tomycin (Amimed, Basel, CH), 2 mM 
 
l
 
-glutamine, and 10  mM
Hepes buffer (Gibco) containing 10% FCS (Gibco) (complete tis-
sue culture medium). CHO and NIH 3T3 cells were obtained
from American Type Culture Collection (Rockville, MD). The
generation and characteristics of the cell line B2.20, a stable CHO
transfectant and 3T3mTNF, both expressing a membrane-bound,
noncleavable, but biologically active deletion mutant of human
TNF (huTNF
 
D
 
1-12), have been described (31). 3T3mTNF(
 
D
 
1-12)
cells were a kind gift of Chiron Corp. (Emeryville, CA).
 
Reagents and Antibodies.
 
Recombinant human TNF, LT
 
a
 
, rab-
bit anti–human TNF polyclonal antibody, and rabbit anti–human
LT
 
a
 
 polyclonal antibody were purchased from Genzyme (Cam-
bridge, MA). The generation and specificity of the TNFR60-
specific antagonistic mAb H398 (11), the TNFR60-specific ago-
nistic mAb htr-1 (13), and the TNFR80-specific mAb MR2-1
(33) have all been described. The generation of the rabbit anti–
human TNFR80 polyclonal agonistic serum, purification of IgG-
fraction thereof and subsequent Fab fragment preparation has also
been described previously (34). As control antibodies, a rabbit
immune serum and a mouse mAb (IR
 
g
 
2), each specific for the
human IFN
 
g
 
 receptor, as well as UPC10 (mouse IgG2a) and normal
rabbit IgG (Sigma Chemical Co., St. Louis, MO) were used.
 
Detection of Cell Surface Expression of TNF Receptors by Indirect
Immunofluorescence.
 
ACH-2 and CEM-SS cells (0.5 
 
3 
 
10
 
6
 
/well)
were dispensed in V-bottom 96-well plates (Nunc, Wiesbaden,
Germany) and washed with ice cold PBS containing 0.1% NaN
 
3
 
.
Cells were incubated in a blocking buffer designed to prevent
nonspecific binding of antibodies containing 10% heat-inactivated
human AB serum and 500 
 
m
 
g/ml human IgG (Sigma) in PBS plus
0.1% NaN
 
3
 
 for 30 min on ice. Specific anti-TNF receptor anti-
bodies (H398, M80 IgG) were added to the cells at a final con-
centration of 50 
 
m
 
g/ml and incubated for an additional 30 min on
ice. Cells were washed twice with cold PBS and resuspended in
 
100 
 
m
 
l of blocking buffer containing secondary antibody (20 
 
m
 
g/ml)
conjugated to a fluorochrome (goat F(ab
 
9
 
)
 
2
 
 anti–mouse IgG-
R-phycoerythrin (Tago Inc., Burlingame, CA) or goat F(ab
 
9
 
)
 
2
 
anti–rabbit IgG-FITC (Jackson ImmunoResearch Laboratories,
West Grove, PA) were mixed with the cells and incubated on ice
in the dark for 30 min. Cells were washed twice with cold PBS
plus NaN
 
3
 
 and fixed in 2% formalin. UPC10 (mouse IgG2a) and
normal rabbit IgG were used as isotype controls, as well as the ad-
dition of the secondary antibody alone to monitor nonspecific
binding. Samples were placed in FACScan
 
Ò
 
 cytofluorimeter and
10,000 events were acquired and analyzed with the 
 
LYSIS II TM
 
software (Lysis, Mountainview, CA) and WinMDI software (pro-
vided by J. Trotter, Salk Institute, La Jolla, CA).
 
Induction of HIV in ACH-2 Cells and Cell Quantification As-
say.
 
ACH-2 cells, in log phase growth, were seeded in 250 
 
m
 
l
(30,000 cells) in 96-well flat-bottom plates (Nunc, Roskilde,
Denmark). 24 h later, inducing agents were added to a final vol-
ume of 300 
 
m
 
l. Cultures were incubated at 37
 
8
 
C in 5% CO
 
2
 
. Cell
free supernatants were removed at 24, 48, and 72 h after induc-
tion and stored at 
 
2
 
20
 
8
 
C until tested for HIV-1 production. At
the end of the experiment (72 h) 1/3 of the cells were removed
from the 96-well plates, placed in U-bottom 96-well plates,
washed two times with PBS to remove serum, and resuspended
in 100 
 
m
 
l of PBS and 100 
 
m
 
l of PBS containing 0.05 g/ml fluo-
rescein diacetate (FDA) (Serva Fein Biochemica, Heidelberg,
Germany). Stock FDA was prepared at 5 mg/ml in acetone and
stored at 
 
2
 
20
 
8
 
C. Cells were incubated in the dark for 30 min at
room temperature and fluorescence was measured with a Titertek
Fluoroscan II (Flow Laboratories, McLean, VA), programmed on
the absolute scale, using a 485-nm excitation filter and a 538-nm
emission filter. The fluorescence values obtained are expressed in
arbitrary units (35).
 
Preparation and HIV-1 Infection of Primary Human Lympho-
cytes.
 
Peripheral blood mononuclear cells were obtained from
the blood of healthy HIV seronegative donors by a combination
of leukapheresis and counter-current centrifugal elutriation as
previously described (36). Lymphocytes were cultured in the
presence of 0.25 
 
m
 
g/ml phytohemagglutinin (Wellcome Diagnos-
tics, Temple Hill, Dartford, UK) for 2 d in complete tissue cul-
ture medium (see ACH-2). Activation was confirmed by the in-
crease in cell size (scattergram, flow cytometric analysis). These
cells were washed, resuspended at 8 
 
3 
 
10
 
6
 
 cells/0.9 ml of me-
dium and infected for 6 h with 0.1 ml of HIV-1/LAV containing
cell-free supernatant (multiplicity of infection 0.14). This virus
(LAV.04/A3.01) was obtained from the AIDS Research and Ref-
erence Reagent Program (Division of AIDS, NIAID, NIH) (37),
and passaged in lymphocytes. After viral adsorption, cells were
washed and resuspended in complete medium supplemented with
100 U/ml of human recombinant IL-2 (Genzyme, Cambridge,
MA). 9 
 
3 
 
10
 
4 
 
cells/well (0.3 ml) were plated in flat-bottom 96-
well plates and cultured for 3 d. Noninfected lymphocytes were
treated under similar conditions. At this point the cells were col-
lected, washed, and resuspended at 10
 
6
 
/ml in complete medium.
 
Evaluation of Cell Membrane Expressed, Noncleavable TNF Action on
ACH-2 or PBLs (Coculture System).
 
The transfectant cells 3T3mTNF
and B2.20 or the control parental cell lines 3T3 and CHO were
trypsinized and plated (1–1.2 
 
3 
 
10
 
4
 
cells/0.25 ml per well) in
96-well flat bottom microtiter plates in complete tissue culture
medium. After 2–3 d, 
 
,
 
80% confluency was achieved. To these
monolayers, ACH-2 cells (32 
 
3 
 
10
 
3
 
) or HIV-1/LAV-infected or
noninfected PBLs (20 
 
3 
 
10
 
4
 
) were added. Plates were centrifuged
at 1,200 rpm for 3 min to produce an evenly distributed layer of
cells. In the case of PBLs, after 16–18 h of coculture (37
 
8
 
C in 5% 
83
 
Lazdins et al.
CO
 
2
 
), the nonadherent cells were removed from the 96-well cul-
ture plates by gently pipetting up and down four times with a
multichannel pipettor. Replicate wells were pooled. Based on the
different sizes, flow cytometric analysis (FACScan
 
Ò
 
; Becton
Dickinson, Mountain View, CA) was used to distinguish PBLs
from 3T3 or 3T3mTNF cells. Though there was an overlap in
the forward scatter characteristics of the two cell populations, it
was found that by using bivariant analysis of light scatter charac-
teristics (i.e., forward scatter versus side scatter) the human PBLs
could be easily distinguished from the 3T3 cells. This was con-
firmed by further cell analysis using direct fluorochrome conju-
gated monoclonal antibodies to CD4 and CD8 (Becton Dickin-
son). For each sample, the percentage of human PBLs was
calculated and used to adjust the total cell recovery.
To quantify the effect of cell membrane bound TNF on viabil-
ity of ACH-2 cells or lymphocytes, two different approaches
were used. Due to the morphological features of the ACH-2
cells, direct quantification of dead cells (apoptotic) was performed
using the propidium iodide/morphology method or the YO-
PRO-1
 
Ô
 
 method. In the case of propidium iodide (38), ACH-2
cells were centrifuged, resuspended in 1 ml PBS (1–2 
 
3
 
 
 
10
 
6
 
), and
fixed in 10 ml pre-cooled (
 
2
 
20
 
8
 
C) 70% ethanol. For labeling of
cellular DNA (apoptosis analysis), stored samples (
 
2
 
20
 
8
 
C) were
washed twice with PBS to remove the ethanol and rehydrate the
cells. Centrifuged cell pellets were resuspended in PBS containing
20 
 
m
 
g/ml of propidium iodide (Molecular Probes, Inc., Eugene,
Oregon) and 100 
 
m
 
g/ml RNase A (Sigma) and incubated over-
night at 4
 
8
 
C. Fragmented nuclei in each sample were evaluated
morphologically using a Leitz Diaplan fluorescence microscope
(Wild Leitz AG, Zürich, Switzerland) equipped with a long pass
filter (580 nM). A total of 200 cells per sample were scored for
nuclear morphology. ACH-2 cells were also examined using la-
beling with YOPRO-1
 
Ô
 
 (39) (Molecular Probes, Inc.). Equal
volumes of cells and dye (final concentration of 10 
 
m
 
M) were
mixed. After 10 min incubation at room temperature, samples
were examined under a fluorescent light microscope (long pass
filter, 520 nm), and fluorescent and nonfluorescent cells were
counted. On the other hand, for PBLs we found that more con-
sistent results within the study period were obtained when the to-
tal number of viable cells at the end of the coculture was deter-
mined instead of scoring dead or damaged cells, which appeared
to be short lasting. For these cells, the YOPRO-1
 
Ô
 
 method al-
lowed to distinguish viable (nonfluorescent) from apoptotic or
dead cells with accuracy.
 
Quantification of HIV Production: Cell-free Supernatant Reverse
Transcriptase Determination.
 
Virus production was determined as
virion-associated reverse transcriptase (RT) activity in the super-
natants of infected cells. RT was measured as described previously
(40) with the following modifications: the reaction mixture was
adjusted to 0.1% Nonidet P-40, 0.8 mM EDTA, and 10 
 
m
 
g/ml
of poly(A) with 0.16 
 
m
 
g/ml oligo(T) as the template primer. The
assay was performed in a 96-well format.
 
Results
 
Inhibition of TNF and LT
 
a
 
 Induced HIV Production by
TNFR Selective Antagonistic Antibodies.
 
To assess the role
of the two TNFRs in TNF-mediated activation of HIV
production in ACH-2 cells, membrane expression of both
TNFR60 and TNFR80 was verified by immunofluores-
cence flow cytometry (Fig. 1). In contrast, the non HIV-
infected parental cell line CEM only expressed TNFR60,
suggesting an induction of TNFR80 in ACH-2 cells dur-
ing establishment of latent HIV infection.
Next, HIV replication was induced by treatment of cul-
tures with 10 ng/ml TNF or 100 ng/ml of LT
 
a
 
, concentra-
tions typically evoking 70–90% of maximum HIV produc-
tion (data not shown). TNF and LT
 
a
 
 dependence of RT
induction was affirmed by addition of anti TNF and anti
LT
 
a
 
 mAbs, respectively, resulting in a full suppression of
supernatant RT activity in each case (Fig. 2, column 
 
1
 
). To
determine the involvement of the two TNFRs in this re-
sponse, neutralizing Fab fragments of receptor-specific anti-
bodies (27, 34) were used for receptor blockade. Treatment
of ACH-2 with TNFR60-specific H398 Fab provided, on
average, 75% reduction (Fig. 2, column 
 
2
 
). By contrast,
TNFR80-specific antagonists (M80 Fabs) caused only a minor
(
 
z
 
20–25%) inhibition of TNF-induced supernatant RT
activity. The same inhibition profile was obtained, when
cells were stimulated with LT instead of TNF (Fig. 2), in-
dicating that both cytokines predominantly employ the
TNFR60 for signaling HIV replication.
 
Induction of HIV Replication by TNFR-specific Agonistic An-
tibodies.
 
To further scrutinize the individual role of the
two TNFRs in induction of HIV, we used agonistic mono-
clonal (htr-1, MR2-1) and polyclonal (M80) antibodies
against TNFR60 and TNFR80 to substitute for TNF in this
response. Stimulation with the TNFR60 agonist htr-1 in-
duced a strong response similar to saturating concentrations
of TNF (Fig. 3), indicating that selective TNFR60 trigger-
ing is sufficient to induce maximum TNF responses with
respect to RT activation. However, selective TNFR80
triggering by either polyclonal (M80) (Figs. 3 
 
A
 
 and 4 
 
A
 
)
or monoclonal (MR2-1; Fig. 3 
 
B
 
) receptor-specific anti-
bodies induced significant RT activity in ACH-2 cells, too,
reaching 35–50% of the maximum response induced by
TNF or htr-1 stimulation (Figs. 3 and 4 
 
A
 
). Specificity was
Figure 1. Coexpression of TNFR60 and TNFR80 in ACH-2 cells.
TNFR expression was determined by indirect immunofluorescence flow
cytometry analyses using TNFR60-specific monoclonal (H398) and
TNFR80-specific polyclonal antibodies (M80) and FITC-conjugated sec-
ondary reagents as described in Materials and Methods. The open histo-
gram represents staining by control antibody, fluorescence intensity ob-
tained by staining with receptor-specific antibodies is shown in black. 
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controlled by the use of mono- and polyclonal antibodies
directed against the huIFN
 
g
 
 receptor, which exerted no
HIV-inducing activity (56 and 59 cpm, respectively, versus
a background value of 66 cpm). Accordingly, TNFR80 is
also linked to signal pathways leading to HIV replication.
The induction of autocrine TNF has been described as a
mechanism for stimulation of HIV production in the
monocytic cell line U1 (29). Whether endogenous TNF
production is involved in TNFR-selective activation of
HIV replication in ACH-2 cells was assessed by the use of
neutralizing anti-TNF antibodies. The data obtained show
that neither TNFR60- nor TNFR80-mediated induction
of RT activity can be inhibited by anti-TNF antibodies
(Fig. 3 
 
B
 
) suggesting a direct TNFR mediated induction of
HIV production.
Because each of the TNFR-specific agonistic antibodies
independently elicited HIV production in ACH-2, it was
of interest to investigate whether the combined action of the
two receptor-specific antibodies induces a further increase
in RT activity. Unexpectedly, when the receptor selective
agonists were used in combination, each at its optimum ac-
tivating concentration, the cellular response of ACH-2 was
less than that expected from addition of the individual re-
sponses and even less than the response obtained by htr-1
stimulation only (Fig. 4 
 
A
 
). When the cell numbers were
determined it became apparent that, although TNF is a po-
tent inducer of virus replication, it simultaneously has an
effect on ACH-2 growth or viability during the three day
culture (Fig. 4, 
 
A
 
 and 
 
B
 
, column 
 
1
 
). This could be a direct
consequence of cell damage due to production and release
of virions or alternatively reflect an independent action of
TNF on this particular cell line. Microscopical analyses of
ACH-2 confirmed that TNF treated cultures not only con-
tain a reduced total cell number, but also a significant pro-
portion of trypan blue positive cells (25 vs. 5% in untreated
cultures; data not shown), indicating that TNF-induced
cell death is at least in part responsible for the observed re-
duction in cell numbers. Interestingly, each of the agonistic
antibodies studied here, also when used at a maximum RT
inducing concentration, showed less effect on cell numbers
when compared to TNF treated ACH-2 (Fig. 4 
 
B
 
). A com-
bination of both receptor-specific agonists, however, in-
duced an enhanced cytotoxic effect, even exceeding that of
saturating TNF concentrations (Fig. 4 
 
B). These data sug-
gest that a major reason for the lack of an additive RT en-
hancing effect of the two receptor-specific agonistic anti-
bodies is due to a predominant induction of cell death in
Figure 2. Inhibition of TNF and LT induced HIV production by
TNFR-specific monovalent antibody fragments. ACH-2 cells were left
untreated or were preincubated for 1 h at 48C with 10 mg/ml of the re-
spective monoclonal or polyclonal reagent before culture for 3 d in the
presence of TNF or LT as indicated. Lanes 1, anti TNF/anti LT, respec-
tively; lanes 2, anti TNFR60 (H398Fab); lanes 3, anti TNFR80 (M80Fab);
lanes 4, control Fab. Data presented are the mean valuesSEM from three
independent experiments (triplicate cultures) in the case of TNF and
mean valuesSD from one experiment in the case of LT. Data are ex-
pressed as relative supernatant RT activity in % of the positive control
(TNF- and LTa-treated cells, 10 and 100 ng/ml, respectively. The mean
induced supernatant RT activity for individual experiments was between
525 and 1,100 cpm/ml).
Figure 3. Induction of HIV
production by agonistic TNFR-
specific antibodies. (A) ACH-2
were cultured in the presence
of the indicated dilutions of
TNFR60-specific mab htr-1
(hybridoma supernatant, d) or
TNFR80-specific antiserum M80
(s) and supernatant RT activity
was determined after 72 h. For
comparison, control cultures
were set up in parallel with un-
stimulated cells and TNF (10 ng/
ml)-treated cells. Shown are the
mean values SD of triplicates of a
typical experiment (n 5 3). Basal
supernatant RT activity of un-
treated cells (60 cpm/ml) has
been subtracted and data are ex-
pressed in percentage of the pos-
itive control (10 ng/ml TNF: 925 6 55 cpm/ml 5 100%). (B) ACH-2 cells were stimulated for 72 h with htr-1 (hybridoma supernatant 1/100), M80 IgG
(4 mg/ml) or MR2-1 (2 mg/ml) in the absence (open bars) or presence (filled bars) of 10 mg/ml of a neutralizing anti-human TNF antibody. Data shown
are the mean values SD of six replicate cultures expressed  in percentage of the RT activity induced by 10 ng/ml TNF (100% 5 934 6 126 cpm, the back-
ground of 66 cpm has been subtracted).85 Lazdins et al.
ACH-2. This effect was not seen when either of the
TNFR-specific antibodies was combined with an irrelevant
control antibody (data not shown).
Enhancement of TNF-induced Cell Death by TNFR80-spe-
cific Agonistic Antibodies. The previous set of experiments
had indicated that TNFR-specific agonistic antibodies in
combination can induce an ACH-2 cell response pattern
distinct from that inducible by TNF. To determine which
of the two TNFRs is triggered differentially by natural
ligand versus agonistic antibody, we titrated the antibodies
into ACH-2 cultures stimulated by a constant concentra-
tion of TNF. In all experiments the TNFR60 agonist htr-1
displayed no significant additional effects on either TNF-
induced RT induction or growth inhibition (data not
shown), whereas the TNFR80 agonist M80 strongly di-
minished the TNF-induced RT induction and enhanced
the TNF-induced cytotoxicity in parallel. Although the
quantity of these M80 effects varied considerably within
the four experiments performed, they were significant in all
cases and could even lead to a total inhibition of RT induc-
tion, paralleled by killing of all ACH-2 cells at the end of a
three-day culture (Fig. 5). To achieve this activation of
TNFR80, complete antibodies were required, as Fab frag-
ments of the agonist M80 showed no effect (Fig. 5). In the
presence of the TNFR60 antagonistic antibody H398, not
only virus replication (Fig. 2) but also the TNF dependent
cell death was fully reverted (data not shown). Together,
these data suggest that efficient induction of cell death in
ACH-2 requires cooperative signaling via both TNFRs.
Induction of Apoptosis but not HIV Replication by the Mem-
brane form of TNF. The enhancement of cell death, upon
combined activation of both TNFRs, either by agonistic
antibodies or by TNF plus agonistic antibodies specific for
TNFR80, pointed to a differential triggering of TNFR80
by the soluble form of the natural ligand versus receptor-
specific antibodies. Because we have recently identified
membrane TNF (mTNF) to be the physiological equiva-
lent to antibody-mediated TNFR80 activation (31), we in-
vestigated the role of mTNF in induction of HIV replica-
tion and apoptosis in HIV-infected cells. In a first set of
experiments, a stable transfectant cell line, 3T3mTNF, ex-
pressing an exclusively membrane bound, nonsecretable
mutant form of TNF has been used in coculture experi-
ments with ACH-2 cells and compared to the RT activity
induced by recombinant, soluble TNF (sTNF). Different
mTNF-expressing cell lines have been recently shown to
be superior to optimum concentrations of sTNF in the in-
duction of a variety of cellular responses (31, 41, 42). As
predicted from the data obtained upon combined TNFR
antibody stimulation (Figs. 4 and 5), mTNF was found to
be a rather poor activator of HIV replication in ACH-2
cells. A representative experiment is shown in Fig. 6,
where coculture of ACH-2 with 3T3mTNF resulted in
,10% of the RT activity induced with low concentrations
of sTNF (0.3 ng/ml).
Control of cell numbers at the end of a three-day culture
revealed massive cell death in the HIV-infected cell line
cocultured with mTNF-expressing transfectants. This was
readily detectable by microscopical analysis, although a reli-
able quantification of cell numbers by the FDA method
was not possible because of the high background values
from the NIH 3T3 cells. To quantify this effect, we used
the cell line B2.20, a CHO clone transfected with the non-
Figure 4. Coactivation of TNFR60 and TNFR80 downregulates HIV
production and enhances cell death. ACH-2 cells were cultured for 3 d in
the presence of TNF (100 ng/ml) and TNFR-specific antibodies (htr-1,
1/50; M80, 40 mg/ml) as indicated. (A) RT activity (mean values SD of
five replicate cultures) was determined in the supernatants as described in
material and methods. (B) Total cell number of ACH-2 was determined
by the FDA method from the groups shown in A in parallel. Data are ex-
pressed as relative cell numbers (100% 5 untreated cells).
Figure 5. TNFR80 enhances TNF mediated cytotoxicity in ACH-2
cells. ACH-2 cells were cultured in triplicates with TNF (10 ng/ml) in
the presence of the indicated concentrations of the TNFR80-specific ag-
onist M80 (filled circle) or Fab produced from purified M80 IgG (open
square). Shown is one experiment out of a total of four with similar results.
(A) Supernatant RT activity (mean values SD) was determined after 3 d
of culture. (B) The total cell number of ACH-2 was determined by the
FDA method. Data are expressed as the relative cell numbers (100% 5
control cells in the absence of TNF, mean values 6 SD).
Figure 6. Membrane TNF
expressing transfectants fail to in-
duce HIV replication. ACH-2
cells were cultured alone in the
absence or presence of TNF (30,
0.3 ng/ml) or were cocultured
with transfectants expressing
mTNF. Supernatant RT activ-
ity was determined after 3 d of
coculture. Shown are the mean
values 6 SD of six replicate cul-
tures from a representative ex-
periment (n 5 3) performed
with 3T3mTNF cells.86 Membrane TNF Signals Cell Death of HIV-infected Cells
cleavable form of human TNF (31). These cells are easily
distinguishable by size and morphology from ACH-2 cells.
As shown in Table 1, the ACH-2 cell recovery after 22 h
of coculture with B2.20 cells was significantly reduced
compared to ACH-2 cocultured with control CHO and
even less compared to cultures in the presence of high con-
centrations of soluble TNF. This clearly correlated with a
higher number of apoptotic cells present in the ACH-2/
B2.20 cocultures at this time point, indicating that induc-
tion of cell death is more efficient or follows a faster kinet-
ics when mTNF instead of sTNF was the activating ligand.
Furthermore, in accordance with the results obtained with
3T3mTNF cocultures (Fig. 6), it was also clear from this
experiment that sTNF induced strong HIV (RT) produc-
tion, while this was not the case in the ACH-2/B2.20 co-
culture (Table 1). According to these observations, the fail-
ure of mTNF to promote virus replication may thus be
directly related to a preferential activation of apoptotic pro-
cesses in HIV-infected cells preceding the production of
infectious virus particles.
To confirm the above described observations in a cellu-
lar system that reflects more closely the in vivo situation,
we studied the role of mTNF in induction of apoptosis and
virus production in HIV-infected, PHA-activated periph-
eral blood lymphocytes. The effect of mTNF was com-
pared to that of sTNF in HIV-infected and noninfected
PBLs. Fig. 7 shows results obtained in independent experi-
ments with three different blood donors. 16–18 h after
onset of cocultures, a significantly higher reduction in viable
cell numbers was observed in all cultures containing mTNF
expressing 3T3 cells as compared to cultures with control
3T3 cells plus high concentrations of sTNF. Although
mTNF was found to induce apoptosis in both, the infected
and the noninfected, PHA-activated T cells, in two out of
the three donors examined here (numbers 2 and 3), an ap-
parent preferential kill of the HIV-infected population
(number of viable cells 13 and 30% of control) as compared
to noninfected cultures (number of viable cells 50 and 58%
of control) was observed (Fig. 7 A). More revealing, the
T cells surviving a 16 h 3T3mTNF coculture were signifi-
Table 1. Membrane TNF Expressing B2.20 Cells Induce 
Apoptosis but Not HIV Replication in ACH-2 Cells
Treatment Cell No.* Apoptotic Cells‡ RT activity§
3103 % cpm/ml
None 111 4 38 6 8
sTNF 93 18 212 6 20
CHO 125 6 27 6 5
B2.20 68 28 54 6 15
ACH-2 cells were seeded at 125 3 103 cells/well, in the absence or
presence of sTNF (30 ng/ml) or in wells containing monolayers of
CHO or B2.20 cells as described in Materials and Methods. 22 h after
onset of cultures, 10 ml of supernatant was removed and RT activity
determined. Thereafter, the nonadherent ACH-2 cells were removed
from the wells (60 wells for each experimental condition), pooled, and
counted.
*Average calculated number of cells recovered per well.
‡The cells were further stained with YOPRO-1Ô, 200 cells for each
group were counted and cells displaying fragmented or condensed nu-
clei were scored as apoptotic.
§Mean values 6 SD of six replicates. 
Figure 7. Effect of 3T3mTNF
cells on in vitro HIV-1-infected
and noninfected human lympho-
cytes. PBLs prepared from three
different healthy blood donors
were in vitro activated with
PHA (0.25 mg/ml) for 2 d, left
noninfected or were infected
with HIV-1/LAV. 3 d later, acti-
vated lymphocytes were plated
on a near confluent monolayer of
mTNF expressing 3T3mTNF
transfectants (mTNF) or 3T3
control cells without (control) or
with sTNF (10 ng/ml) (sTNF)
(six replicate cultures). At the
onset of cocultures, the RT ac-
tivity of HIV-infected cells was
2219 6 247 (donor 1), 585 6 88
(donor 2) and 332 6 62 (donor 3)
cpm/ml. (A) 16 h after coculture,
replicate cultures were pooled,
the YOPRO negative number
of cells analysed and the average
number of viable cells per well
was determined. Black bars indicate noninfected cells and grey bars indicate infected cells. (B) HIV-1 production (cell-free supernatant RT activity) of
the infected lymphocytes from the three donors upon separation from the 3T3 coculture after 16 h and replating in wells without 3T3 for an additional
2 d. The carry over of 3T3 cells was minimal as assessed by the absence of adherent cells after the 2-d culture. Each group represents the mean 6 SD
from six replicate cultures.87 Lazdins et al.
cantly impaired in their virus production capacity, as re-
vealed upon transfer and reculture in the absence of mTNF
expressing cells (Fig. 7 B), suggesting that the number of
infected, virus producing cells has been reduced. In con-
trast, upon replating HIV-infected T cells pretreated for 16 h
with sTNF RT activity was similar to control cultures.
These data indicate a higher sensitivity of HIV-infected,
primary lymphocytes towards apoptosis induced by mTNF.
Discussion
The aim of this study was to delineate the specific con-
tribution of the two TNF receptors to TNF responses of
HIV-infected T cells. Our data not only show a differential
function of the two TNFRs in regard to activation of HIV
replication, with TNFR60 as the major mediator of HIV
activation, but also provide evidence for TNFR80 as an
important modulator of the cellular response. We show
that TNFR80 is capable of converting, upon appropriate
activation, the response phenotype from promoting virus
replication to induction of cell death.
Based on the existing knowledge of the critical involve-
ment of NF-kB in promoting HIV replication (18–22) and
its activation via TNFR60 signal pathways (23–25) as well
as from observations with the OM-10.1 cell line (26) it was
anticipated to find a dominant role of TNFR60 in HIV in-
duction in the T cell line ACH-2 as well. This holds true
for both TNF and LTa. With regard to TNFR80, we show
by use of two distinct receptor-specific, agonistic reagents
that this receptor is also capable to convey activation signals
for virus production in this T cell line. Our data further
show that the TNFR80-mediated activation of HIV repli-
cation in ACH-2 cells is likely to be a direct effect and not
an indirect action via endogenously produced TNF, the
latter potentially activating, in an autocrine feedback loop,
HIV replication via TNFR60. A direct TNFR80-mediated
signal pathway to HIV replication is in full accordance with
the recent demonstration that, in T cells, TNFR80 can
trigger NF-kB activation (43). As both TNFRs employ a
common receptor associated signal transducer, TRAF 2,
for NF-kB signaling (44, 45), it appears likely that shared
signal pathways are used by each of the receptor subtypes to
induce HIV replication in ACH-2 cells.
Quite unexpected, however, was our observation with
the T cell line ACH-2 and acutely HIV-infected PBLs that
a simultaneous triggering of both TNFRs with agonistic,
receptor-specific antibodies (ACH-2) or membrane TNF-
expressing cells (ACH-2, PBL) was not equivalent to a
treatment with maximum activating concentrations of sol-
uble TNF. Rather, this resulted in a response counteracting
virus replication, namely rapid induction of apoptosis. Al-
though, at present, we cannot rule out that upon combined
activation of both TNFRs, unknown signal pathways neg-
atively controlling HIV replication become effective inde-
pendent of induction of apoptosis, the available in vitro
data suggest a correlation between reduction in viable cell
number and inhibition of virus replication.
The differential signal capability of TNFR-specific ago-
nistic antibodies versus sTNF could be mapped to TNFR80,
yet the shift of the cellular response towards enhanced cell
death was brought about by cooperative signaling via both
receptors, in which mTNF or antibody mediated induction
of TNFR80-elicited signal pathway(s) determine(s) the over-
all outcome of the cellular response. This interpretation is
based on the following findings: (a) stimulation with a po-
tent TNFR60 agonist, htr-1, led to the induction of a full
response with respect to HIV induction in ACH-2 cells,
making TNFR80 signaling dispensable for this action; (b)
with respect to concomitantly induced apoptosis of HIV-
infected cells, signaling via both receptors is evident from a
limited (htr-1) or virtually no (M80) cytotoxic activity of
each of the agonistic antibodies on their own as compared
to TNF; (c) the enhanced apoptosis upon treatment with
sTNF plus TNFR80-specific antibody, but not sTNF plus
TNFR60-specific antibody, suggests that a distinct signal
quality is transduced via TNFR80, which is not inducible
by soluble TNF.
The superior capability of agonistic antibodies over sTNF
to induce cellular responses via TNFR80 is not without
precedence (31, 46), and evidence for cooperative signaling
of both TNFRs, leading to quantitatively and/or qualita-
tively distinct responses, has been obtained by us in several
other experimental systems (31, 41, 42, 47, 48). It is evi-
dent from these in vitro studies that mTNF, unlike sTNF,
is an efficient inductor of TNF responses due to simulta-
neous activation of both TNFR subtypes. According to
these studies, the underlying mechanism of mTNF versus
sTNF action resides, at least in part, in a 10-fold higher off
rate of sTNF at TNFR80 as compared to TNFR60, result-
ing in a low signal capacity of TNFR80 under these condi-
tions. In contrast, binding of mTNF by its cognate receptors
during cell–cell contacts is likely to persist for a time long
enough to ensure the formation of active signaling com-
plexes at TNFR80, too. Agonistic antibodies mimic this stable
receptor ligand interaction. Consistent with this interpreta-
tion is the finding that a nonagonistic, receptor-specific an-
tibody, which stabilizes sTNF binding to TNFR80, restores a
high signal capacity of this receptor (31).
A possible in vivo relevance mTNF in conveying pro-
tective TNF responses during host defense against parasites
and tumors had already been suggested previously (49–51),
although, at that time, the underlying mechanisms for a su-
perior action of mTNF were not understood. We now ex-
tend these findings by showing that in in vitro models of
acute HIV infection and HIV latency, mTNF promotes
apoptosis of infected T cells rather than virus replication
and that the simultaneous application of TNFR80-specific
agonistic antibodies can convert a response to sTNF into a
mTNF like response.
What are the implications of the data presented here for
understanding of HIV replication in vivo? Provided TNF
plays a similar role for propagation of virus infection in
vivo, our results point to a potentially important regulatory
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differential response to soluble versus membrane bound
TNF. Accordingly, both the TNFR status of infected cells
and the relative concentrations of soluble versus membrane
TNF in their close vicinity should influence the type of re-
sponse. TNFR80 expression is highly regulated and, in par-
ticular in lymphoid cells, activation dependent (9, 10, 12). As
efficient induction of apoptosis by mTNF in HIV-infected
T cells requires cooperative signaling via both TNFRs,
regulation of TNFR80 expression could ensure selectivity.
The constitutive TNFR80 expression in the chronically
infected ACH-2, but not the parental CEM cell line, could
be a correlate of the situation during primary infection of
lymphocytes. Further, for the OM-10.1 cell line, another
in vitro model of chronically infected cells, it has been shown
that TNFR60 activation not only caused HIV replication,
but simultaneously a selective upregulation of TNFR80
expression (26), thus potentially rendering this HIV-infected
cell line more sensitive to apoptosis. In this context, it is im-
portant to note that TNF-induced apoptosis appears, at least in
vitro, not exclusively restricted to HIV-infected cells.
Rather, it has already recently been shown that, upon re-
peated in vitro activation, T cells can undergo apoptosis via
a TNF/TNFR80-dependent pathway, too (52). The par-
ticular role of membrane TNF in this process becomes ap-
parent from the data presented here, showing a greater
apoptotic response to mTNF as compared to sTNF also on
noninfected, but PHA-activated T cells. Despite this prin-
ciple sensitivity of in vitro polyclonally activated T cells to
TNF mediated apoptosis, we have here obtained evidence
for a higher sensitivity of HIV-infected versus noninfected
peripheral blood lymphocytes towards apoptosis induced
by mTNF. More revealing, only in the presence of mTNF
expressing cells, but not sTNF, was a reduction of virus
production observed in acutely infected lymphocyte cul-
tures. The intracellular mechanism(s) causing increased sen-
sitivity of HIV-infected cells to mTNF-induced apoptosis
are unknown at present. 
Soluble TNF is proteolytically derived from its mem-
brane precursor, and mTNF expression has been verified
on activated monocytes, T cells and endothelial cells (42,
53, 54). In the context discussed here it is interesting to note
that HIV-specific CD41 T cell clones express membrane
TNF (54). Accordingly, in vivo, not only macrophages but
also virus-specific T cells are a potential source of mTNF and
could, independent of a T cell receptor mediated cytolytic
effector function, signal cell death to TNFR60 and TNFR80
coexpressing, HIV-infected cells. However, mTNF-expres-
sing cells could potentially also contribute to the bystander
effect by signaling apoptosis to those non infected, yet acti-
vated lymphocytes that coexpress sufficient amounts of both
TNF receptors. Independent on the in vivo frequency of
the latter, the model predicts that all nonactivated and thus
TNFR80 negative T cells (likely the vast majority) would
be spared.
Based on the data presented, we hypothesize that an in
vivo prevention of proteolytic processing of membrane
TNF to its soluble form, e.g., by TNF-specific protease in-
hibitors (55–58), should not only downmodulate systemic
toxicities associated with high serum TNF levels (55), but
also could limit virus replication by enhanced elimination
of HIV-infected cells. Further studies in appropriate animal
models will be necessary to evaluate whether or not an in-
hibition of TNF processing or antibody mediated TNFR80
coactivation are effective means to reduce the number of
HIV-infected T cells in vivo and could be employed to-
gether with other antiviral strategies.
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